000 02340cam a2200349 a 4500
003 EG-GiCUC
005 20250223031043.0
008 140918s2014 ua dh f m 000 0 eng d
040 _aEG-GiCUC
_beng
_cEG-GiCUC
041 0 _aeng
049 _aDeposite
097 _aPh.D
099 _aCai01.11.07.Ph.D.2014.Mo.S
100 0 _aMona Mohsen Ahmed Abouelghar
245 1 0 _aStudy of Tumor Necrosis Factor-Related Apoptosis Inducing Ligand (TRAIL) mRNA Expression in Patients with Systemic Lupus Erythematosus/
_cMona Mohsen Ahmed Abouelghar ; Supervised Safaa Mostafa Elkaraksy , Noha Mohamed Hosny Shahin , Naglaa Mohamed Kholoussi
246 1 5 _aدراسة التعبير للحمض النووي الريبوسومى المرسل لعامل النخر للأورام المرتبط بمحفز موت الخلايا فى مرضى الذئبة الحمراء
260 _aCairo :
_bMona Mohsen Ahmed Abouelghar ,
_c2014
300 _a88 P. :
_bcharts , facsimiles ;
_c25cm
502 _aThesis (Ph.D.) - Cairo University - Faculty of Medicine - Department of Clinical and Chemical Pathology
520 _aTRAIL (APO-2 ligand) is a transmembrane (type II) glycoprotein which also belongs to the TNF superfamily. TRAIL triggers apoptosis through interaction with the death receptors Death Receptor (DR4) (TRAIL-R1) and (DR5) (TRAIL-R2). There are several indications that TRAIL could be involved in the pathophysiology of autoimmune diseases in general and systemic lupuserythematosus (SLE) in particular. The aim of this study was to investigate TRAIL m RNA expression levels in peripheral blood mononuclear cells(PBMCs) from patients with SLE and to study the association between the results and various clinical and laboratory data of the patients in order to assess the possible role of TRAIL in SLE pathogenesis and its relation to disease activity
530 _aIssued also as CD
653 4 _aReal time PCR
653 4 _aSystemic lupus erythematosus
653 4 _aTumor necrosis factor related apoptosis inducing ligand
700 0 _aNaglaa Mohamed Kholoussi ,
_eSupervisor
700 0 _aNoha Mohamed Hosny Shahin ,
_eSupervisor
700 0 _aSafaa Mostafa Elkaraksy ,
_eSupervisor
856 _uhttp://172.23.153.220/th.pdf
905 _aAml
_eCataloger
905 _aNazla
_eRevisor
942 _2ddc
_cTH
999 _c47423
_d47423